Morgan Stanley maintains BridgeBio Pharma at Overweight, raises price target to $91 from $88
Morgan Stanley kept its Overweight rating on BridgeBio Pharma and increased its price target to $91 from $88, suggesting a 16.4% upside from the Nov 12 close of $78.17. Recent analyst price targets for the company range from $88 to $120.
How this was made

The 30-second read
Why it matters
This is primarily a sentiment and positioning update for BBIO rather than a new fundamental disclosure. The main tradable element is the PT change and how it may influence near-term expectations relative to other recent targets.
Market read
Traders may monitor whether this PT move triggers additional revisions across the Street, but the article itself contains no new company-specific operational or clinical data.
What to watch
The article does not state the thesis behind the PT increase, so traders may discount it if it is not tied to a near-term catalyst.
Background
The piece summarizes an analyst action from Morgan Stanley on BridgeBio Pharma, including the updated price target and implied upside versus a recent close.
Ticker impact
Morgan Stanley maintained BridgeBio Pharma at Overweight and raised its price target to $91 from $88, implying a higher upside versus the Nov 12 close.
Likely modest upward bias as traders price in the higher target, with follow-through depending on whether other analysts adjust.
The article provides a specific PT change and rating maintenance, but no new clinical, regulatory, or financial datapoint from BridgeBio itself.
Market effects
Limited spillover to biotech broadly; this is a single-name analyst target change.
No direct regional market linkage indicated.
No global macro or cross-market catalyst described.
Counterpoint
Analyst price-target hikes can lag or fail to translate into sustained price moves if the underlying catalysts (trial/regulatory milestones) are unchanged.
Key entities
- companyBridgeBio Pharma
Subject of the analyst action, with Morgan Stanley maintaining Overweight and raising the price target to $91.
- analyst_firmMorgan Stanley
Issued the rating maintenance and price-target increase referenced in the article.



